Technology | May 14, 2012

Sorin Group Announces FDA Approval, Launch of Implantable Heart Device Leads

New pacing, defibrillation and left ventricular leads, combined with Sorin Group’s innovative implantable devices enable effective management of arrhythmias and heart failure

May 14, 2012 — Sorin Group at the Heart Rhythm Society (HRS) scientific sessions announced U.S. Food and Drug Administration (FDA) approval and commercial launch for a full portfolio of pacing, defibrillation and left ventricular leads. Designed for effective electrical performance and durability, each of the three lead series – Tilda pacing leads, Vigila defibrillation leads and Celerity left ventricular leads – include multiple sizes and features to enable physicians to match their implant preferences with individual patient needs.

In addition to a flexible silicone lead body, steroid-eluting tips that reduce inflammation, and iridium fractal coated electrodes with proven electrical performance, each lead family offers its own additional features:

  • Tilda pacing leads include a flexible lead body and distal tip and are designed for easy implantation and predictable performance.
  • Vigila defibrillation leads feature a symmetrical lead body and thick outer insulation. Convex shock coils embedded in silicone insulation are engineered to minimize tissue in-growth.
  • Celerity left ventricular leads have a flexible co-radial body, and are designed to facilitate access and ensure stability in targeted pacing sites regardless of patients’ coronary venous anatomies.

“Sorin Group is bringing important new implantable heart rhythm and heart failure systems to the United States, an important and growing market for Sorin Group. The leads are important additions that will help the U.S. physicians manage their patients,” said Stefano Di Lullo, Sorin Group, president of the CRM business unit. “We’ve received tremendous feedback from physicians in other international markets about the reliability of these leads, and we are committed to continuing to deliver outstanding technologies to enhance clinical performance and patient outcomes in the United States and throughout the world.”

For more information: www.sorin.com

 

Related Content

A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Heart Rhythm 2019 study shows travelers with common cardiac devices can pass through without restrictions or precautions. HRS 2019, #HRS #HRS19

A new study shows travelers with common cardiac devices can pass through airport body scanners without restrictions or precautions.

News | EP Lab | May 14, 2019
May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), su
News | EP Lab | May 13, 2019
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their
Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Feature | EP Lab | March 22, 2019
March 22, 2019 — The U.S.
Medtronic Tyrx Envelope Significantly Reduces Major Infections in Cardiac Implantable Device Patients
News | EP Lab | March 20, 2019
Results from the landmark Worldwide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT) demonstrated...
Videos | EP Lab | February 27, 2019
This is a virtual heart with the same electrophysiology characteristics as the real patient being developed to help o
Seth Worley, M.D., senior consultant, section of cardiac electrophysiology, MedStar Heart and Vascular Institute, developed tools and techniques to optimize transvenous left ventricular (LV) lead implantation, including the I-CRT approach. Here he holds the tools that he personally developed for left ventricular lead implantation to treat heart failure. Photo courtesy of MedStar Heart and Vascular Institute at MedStar Washington Hospital Center.

Seth Worley, M.D., senior consultant, section of cardiac electrophysiology, MedStar Heart and Vascular Institute, developed tools and techniques to optimize transvenous left ventricular (LV) lead implantation, including the I-CRT approach. Here he holds the tools that he personally developed for left ventricular lead implantation to treat heart failure. Photo courtesy of MedStar Heart and Vascular Institute at MedStar Washington Hospital Center.

Feature | EP Lab | January 21, 2019 | Matthew S. McKillop, M.D., FACC, FHRS, and Seth J. Worley, M.D.
Interventional...
An implanted ICD showing its three venous leads. These multiple CRT leads can cause issues when they need to be replaced and are abandoned with new leads put over them in the SVC, which may require lead extraction.

An implanted ICD showing its three leads in the venous system. 

Feature | EP Lab | January 13, 2019 | Dave Fornell, Editor
To extract or abandon broken or infected implantable, venous...
Overlay Init